INTRODUCTION
============

Lung cancer is the leading cause of cancer-related deaths worldwide [@B1]-[@B3], twenty-five percent of these belong to the group of neuroendocrine tumors [@B4]. These tumors encompass small-cell lung carcinoma (SCLC), large-cell neuroendocrine carcinoma (LCNEC), as well as typical (TC) and atypical carcinoids (AC) [@B5]. Patients suffering from TC have excellent survival rates with 87-100%, but some present with lymph-node metastasis (4-15%) [@B6]-[@B15]. Atypical carcinoids are more aggressive (survival rate 61-88%) and show higher frequency of nodal metastasis [@B8]-[@B14], [@B16]. According to the WHO classification from 1999, LCNEC was assigned to the non-small cell lung cancers (NSCLC) but shows similar biological behavior as SCLC with a five-year survival rate of 15%-57% [@B4], [@B8]. Up to 20% of all lung cancer incidences are SCLC showing the poorest five-year survival rates with less than 5% [@B4], [@B5], [@B8], [@B15]. High-grade neuroendocrine carcinomas of the lung occur almost exclusively in older patients (median 61 years) with a history of smoking, whereas lung carcinoids occur frequently in never smokers and younger patients (mean 45-55 years) [@B7], [@B15], [@B17], [@B18].

Carcinoid tumors are predominantly treated surgically, metastatic tumors are commonly not sensitive to chemotherapeutic regimes or radiation [@B4], [@B19]. Adjuvant chemo- or radiotherapy should be considered in completely resected AC with mediastinal lymph node involvement [@B6], [@B20], [@B21]. Combinations of chemotherapeutics are usually platinum- or streptozoticin-based [@B20].

For SCLC, chemotherapy with cisplatin plus etoposide is a well-established treatment since these tumors are notably sensitive to chemo- and radiotherapy [@B4]. An optimal treatment for LCNEC is still under investigation due to the relative rarity of this entity [@B4]. As defined by the WHO classification guidelines, LCNEC belongs to NSCLC, leaving it to the physician whether to treat it similarly to SCLC or NSCLC [@B8]. In fact, patients receiving SCLC-based regimens showed a significantly better outcome [@B20], [@B22].

The present study was conducted to identify markers for personalized therapeutic concepts in pulmonary neuroendocrine tumors, potentially leading to an improved clinical management.

MATERIAL AND METHODS
====================

Demographic Data and Study Design
---------------------------------

The study is based on a collective of seventy representative formalin-fixed, paraffin-embedded pulmonary neuroendocrine tumors (17 TC, 17 AC, 19 LCNEC, and 17 SCLC) used for sequencing. For expression analysis, 60 samples were investigated (16 TC and 13 AC, 16 LCNEC and 15 SCLC). The initial diagnosis was re-evaluated by two experienced pathologists (JWO, TMA). Specimens were taken from the Institute of Pathology at the University Hospital Essen (Germany) from 2005 till 2012. TNM-staging was based on the *WHO Classification of Tumours* guidelines (2004) [@B18]. The mean age at date of diagnosis was 58.6 years (median age: 59.0 years; 95% CI: 50.8-66.9 months). Survival data were available for 34 patients with twenty-two reported deaths at the time of data collection. Patients receiving chemotherapy before resection were excluded. The study was approved by the ethical committee of the University Hospital Essen (ID: 13-5382-BO). The investigations conform to the principles outlined in the declaration of Helsinki.

Sample Preparation
------------------

Genomic DNA was isolated on a Maxwell® 16 Research (Promega Corporation, Madison, USA) as recommended in the manufacturer\'s protocol. RNA extraction was performed using the RNeasy FFPE kit (Qiagen, Hilden, Germany) according to the manufacturer\'s recommendations. Nucleic acid quantification was performed using Qubit (Life Technologies, Carlsbad, USA) and Nanodrop 1000 instrument (Thermo Fisher Scientific, Waltham, USA). RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA) at the NanoString nCounter Core Facility at the University of Heidelberg (Germany) by smear analysis.

NanoString CodeSet Design and Expression Quantification
-------------------------------------------------------

Important genes for different tumor-associated signaling pathways were included in the Custom CodeSet using the Standard Chemistry. The CodeSet contained a total of 91 genes and 13 of these genes were considered as potential pharmaceutical targets (*ALK, CDKN2A, EGFR, FAS, FGFR1, FIGF, FLT4, IGF1, IGF2, KDR, MDM2, MET, MTOR)*.

Probe-sets for each gene were designed and synthesized at NanoString Technologies (Seattle, USA). Total RNA (100 ng) from FFPE material was measured at the NanoString nCounter Core Facility at the University of Heidelberg, Germany.

Next-Generation Sequencing
--------------------------

Sample preparation was done using the TruSeq Amplicon - Cancer Panel (Illumina Inc., San Diego, CA, USA) followed by paired-end sequencing on the MiSeq Personal Sequencer (Illumina) according the protocols provided by the manufacturer. The Cancer Panel covered the following 48 tumor-relevant genes (table [1](#T1){ref-type="table"}) including 221 mutation hotspots. Library construction followed the TrueSeq Custom Amplicon - Library Preparation guide.

FastQ-files were aligned against the Hg19 build. For analysis of the aligned reads including variant calling, the software Avadis NGS (Strand Scientific Intelligence, California, USA) was used. Reads with a quality score \<30 were discarded. After removal of SNPs, data filtering was done by excluding variants with \<25 effective variant reads or below 10% variation frequency. Synonymous variants were removed.

Finally, variants were analyzed for their functional impact on the protein-activity by using MutationAssessor (release 2) [@B23] and implementation of the ANNOVAR algorithm [@B24], combining the tools SIFT [@B25], PolyPhen2 [@B26] and MutationTaster [@B27].

Statistical Analysis
--------------------

All statistical analyses were performed using the R statistical programming environment (v3.1.3). For dichotomous factors and linear vectors the Wilcoxon Mann-Whitney rank sum test was applied. For variance analysis of variables with more than two categories the Kruskal-Wallis test was performed. Correlations between linear vectors were analyzed by Spearman\'s rank correlation test. Double dichotomous contingency tables were analyzed using Fisher\'s Exact test. To test dependency of ranked parameters with more than two groups the Pearson\'s Chi-squared test was used. COXPH-model was used to analyze overall survival (OS) and progression-free survival (PFS). PFS was calculated from the first day of chemotherapy until progression, death from any cause, or the last time of follow up. OS was defined as the time from diagnosis until the date of death or last follow-up. Surveillance of PFS and OS was stopped on August 31, 2014. Significant differences in PFS or OS were analyzed by the Wald-test, likelihood-ratio test and Score (logrank) test.

The level of statistical significance was defined as p≤0.05.

RESULTS
=======

Gene Expression in Pulmonary Neuroendocrine Tumors
--------------------------------------------------

Gene expression analysis showed strong differences between tumors of the four different entities, but also within tumors of each subgroup. Most strikingly, *EGFR* gene expression is present in 87.5% of TC, 100% of AC, 65.3% of LCNEC and in 60% of SCLC. Likewise, *FGFR1* is expressed in 97.3% of all carcinoids in a noteworthy manner. Besides, 62.5% of LCNEC and 80% of SCLC show strong expression of *FGFR1*. *MDM2*was strongly expressed in the majority of all samples. 81.3% of TC, 76.9% of AC, 50% of LCNEC and 93.4% of SCLC present gene expression of *MDM2*. *CDKN2A* expression was rare in all low-grade neuroendocrine lung tumors, but present in some carcinomas showing high gene expression.

An overview of cases with increased expression levels is given in figure [1](#F1){ref-type="fig"}, an overview of all expression pattern is shown in table [2](#T2){ref-type="table"}.

Occurrence of Mutations in Pulmonary Neuroendocrine Tumors
----------------------------------------------------------

86 functionally deleterious variants were determined within 13 therapy-relevant genes in 49 out of 70 samples. Four of the variants could be detected in TC, 14 in AC, 30 in LCNEC and 38 in SCLC.

In seven samples (10%; one TC, two AC, one LCNEC and three SCLC), variants in the *EGFR* gene were found, but none of them is known or predicted to activate the receptor. For *ERBB2,*a receptor tyrosine kinase (RTK), closely related to *EGFR*, three different variants could be observed in eleven samples.

Activating *KRAS*variants downstream of these receptors were found in three tumors (two LCNEC and one AC). Additionally, one sample showed activating mutations in the *NRAS* gene locus. *BRAF* variants occurred in three samples (4%), two LCNEC and one SCLC. Five different variants of *PIK3CA* were found in six tumor samples.

Interestingly, *TP53* showed the highest frequency of variants with 31 alterations in 23 samples (33%), whereas the percentage was varying in the different neuroendocrine subtypes. 64.7% of all SCLC and 63.2% LCNEC showed a functional inactivation of P53 via *TP53* mutations. No *TP53* alterations were found in TC or in AC.

A summary of all mutations is given in Supplementary table [1](#SM1){ref-type="supplementary-material"}.

Expression and mutation frequency are summarized in table [3](#T3){ref-type="table"} for each tumor entity.

Association with Clinicopathological Parameters
-----------------------------------------------

*EGFR*, *FLT4* and *FIGF*show highly significant differences in their expression levels between the four investigated tumor entities (p=0.0044, p=0.0054 and p=0.0096, respectively). Elevated *EGFR* gene expression (p=0.0002) is more prominent in carcinoid tumors compared to carcinomas. Also *FGFR1* gene expression presents with significant differences (p=0.0301). Furthermore, upregulated *EGFR* gene expression associated significantly with lower IASLC-Grade (p=0.0005). *FGFR1* as well as *FLT4* show highly significant associations with tumor grade (p=0.0025 and p=0.0061, respectively). High *FIGF* (p=0.0210, HR: 1.40) and *FAS*(p=0.0233, HR: 1.27) gene expression levels seem to be associated with shortened PFS. In high-grade tumors, high *FIGF*mRNA levels identified a group of poor responders to therapy (COXPH: p=0.0347).

The appearance of *TP53* variants was significantly associated with tumor type (p\<0.0001) and is associated with carcinomas. *PIK3CA* shows variants in 5.9% of AC and 23.5% of SCLC, whereas TC and LCNEC present none of these variants (p=0.0116). Tumors infiltrating lymph nodes present with higher frequency of *TP53* variants (p=0.0007), as well as *ERBB2* variants (p=0.0051) or *BRAF* mutations (p=0.0468).

*PIK3CA*variants are associated with shortened OS (p=0.0019, HR: 2.54). Activating mutations in the *KRAS*gene (p=0.0003, HR: \>10) are associated with a higher risk of progression.

DISCUSSION
==========

Until now, studies investigating novel therapeutic approaches for pulmonary carcinoid tumors are lacking due to the rather long overall survival rates of patients with carcinoids. Nevertheless, tumors associated with a syndrome are resistant to chemo- and radiotherapy in most cases. This study is one of the first approaches to investigate a broad spectrum of biomarkers potentially predicting response to different chemotherapeutic agents. For mRNA expression analysis, the NanoString nCounter technology was used and additionally, 221 mutation hotspots were screened via massive parallel sequencing by synthesis.

Erlotinib, gefitinib or icotinib, in second generation also afatinib, are epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKI) used for the treatment of NSCLC harboring activating *EGFR* mutations [@B28]. Pathway activation downstream of EGFR, e.g. by *KRAS* mutations, is known to be a resistance mechanism for EGFR-TKI therapeutic approaches, but also the appearance of resistance mutations within the *EGFR* gene (e.g. p.T790M) has been described [@B29]. Moreover, continued activation of PI3K signaling via mutated *PIK3CA* was identified to abrogate gefitinib-induced apoptosis [@B29]. Further studies confirmed that the PI3K pathway is involved in different resistance mechanisms with respect to EGFR therapy approaches [@B30]. Consequently, different trials using PI-103, a PI3K/mTOR double inhibitor, in combination with EGFR-TKI therapy were initiated.

In our study, none of the tumors showed classical activating mutations in the *EGFR* gene. Of note, eight mutations impairing protein function were found in pulmonary neuroendocrine tumors regardless of the subtype (figure [2](#F2){ref-type="fig"}). A present study revealed that also cases with other non-classical mutations and complex mutational events had similar end-point outcomes to TKI therapy compared with classical activating mutations [@B31]. Besides, anti-EGFR antibody therapy with cetuximab may be a possible alternative. Cetuximab activity in NSCLC was found in tumors that expressed high levels of *EGFR* only [@B32], but also other monoclonal anti-EGFR antibodies were evaluated. These include matuzumab, panitumumab and most promising necitumumab, leading to an increased survival compared to cetuximab [@B33]. In our study, the majority of carcinoid tumors and more than half of all high-grade tumors show strongly upregulated expression levels of *EGFR*; one third of all NELC present with a highly increased *EGFR* gene expression level (figure [2](#F2){ref-type="fig"}). Furthermore, it has been reported that more than half of all carcinoids show increased *EGFR* copy numbers [@B34]. Thus, making them potential targets for monoclonal anti-EGFR antibodies.

Lapatinib is currently approved for patients with *ERBB2*(HER2)-positive metastatic breast cancer in combination with capecitabine after prior therapy with anthracycline, taxane, and trastuzumab [@B35], [@B36]. It is also approved in combination with letrozole in postmenopausal women with ERBB2-positive advanced breast cancer where endocrine therapy is indicated [@B36], [@B37]. Mutations in the *ERBB2* (HER2) gene locus were reported in 1.5%-2% of all NSCLC, but this aberration occurred exclusively in adenocarcinomas [@B38], [@B39]. We found nine patients (13%) harboring the activating p.L785R and the p.R868W. It has been shown that patients with mutations and without amplification of the *ERBB2* gene locus can respond to lapatinib [@B36], [@B39].

Activating *BRAF* mutations were found in two LCNEC and one SCLC. Patients harboring activating *BRAF* mutations are known to be sensitive for therapy with vemurafenib [@B40]. Activation downstream of *BRAF*, primary through *RAS* mutations, is reported to act as a potential resistance mechanism [@B41]. *RAS* mutations were observed in all tumor entities except TC, but never appeared in combination with *BRAF* mutations. The response of pulmonary neuroendocrine tumors harboring *BRAF* mutations to vemurafenib has to be proven in further studies.

A large part of human cancers shows *TP53* inactivation, mostly by mutations or loss of heterozygosity (LOH) of the whole gene locus. Even in *TP53* wild type tumors the functional protein is inactivated resulting from some putative mechanisms of amplification and overexpression of *MDM2*, the physiological inhibitor of P53 [@B42]-[@B46]. MDM2 itself is controlled by the tumor suppressor P14/ARF (encoded by the gene locus of *CDKN2A*). Numerous environmental influences and genetic alterations induced by platin compounds are able to activate P53 by post-translational modifications, which results in cell cycle arrest, cellular senescence, or apoptosis [@B47]. Nutlin-3A, a cis-imidazoline analogue, is a potent and selective MDM2 inhibitor [@B48], [@B49] that prevents MDM2-TP53-interaction by binding to the hydrophobic binding pocket of MDM2 leading to an immediate reactivation of P53 [@B48], [@B50], [@B51]. It is currently tested in a phase I clinical trial (NCT01143519, NCT00623870) [@B51]. Second-generation MDM2 inhibitors (RG7112, RO5045337, Idasanutlin, RG-7388, DS-3032b, SAR405838, CGM-097, MK8242, HDM201 etc.) are currently tested in phase I-III trials for various diseases (NCT01877382, NCT02319369, NCT00559533, NCT01985191, NCT02016729, NCT02343172 etc.)

For high-grade neuroendocrine lung tumors, *TP53* mutations were found in the majority of tumors (figure [3](#F3){ref-type="fig"}A). As described, the main alternative mechanism seems to be LOH, so *MDM2* inhibition may not be successful. In contrast, carcinoids lack genetic alterations of *TP53*, but about 80% of samples show a dramatically high *MDM2* gene expression level (figure [3](#F3){ref-type="fig"}B). Additionally, *CDKN2A* inhibiting *MDM2* is absent in most pulmonary carcinoids. Therefore, pulmonary carcinoids seem to be an ideal target for Nutlin-3A therapy. A major issue with carcinoid tumors is the rarity of the disease and therefore it is difficult to conduct such studies. Also, there is an issue if drugs such as; everolimus could be administered as adjuvant therapy and for how long after surgery [@B52]. Everolimus could be used as treatment in the case that surgery is not possible, or could be used as adjuvant therapy in the case that surgery is not possible and only endoscopic debulking procedures are possible. The length of the therapy administration depends on multiple factors such as local disease progression and drug side effects. There are still many matters to clarify as disease diagnosis and management. [@B53]-[@B55]

CONCLUSION
==========

Carcinoids of the lung show long survival rates, but sometimes progress to a systemic disease. Carcinoids with a syndrome are resistant to chemo- and radiotherapy and new therapeutic approaches are needed. Based on our results, therapeutic approaches with MDM2 inhibitors and monoclonal anti-EGFR antibodies may be a promising novel therapeutic approach and need to be confirmed in further *in vitro* and *in vivo* studies.

SUPPLEMENTARY MATERIAL {#SM0}
======================

###### 

Supplementary table 1.

###### 

Click here for additional data file.
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![Percentage of tumours showing highly increased gene expression. One-third of all pulmonary neuroendocrine tumours show strong overexpression of *EGFR* and *FGFR1*. Of note, also one-third of tumours show high *IGF2* expression and 10% present with high *IGF1* expression. More than 50% of all tumours show highly elevated *MDM2* expression.](jcav07p2165g002){#F1}

![The plot in the upper row shows the percentage of tumours with *EGFR* variants predicted to influence protein function. Nevertheless, classical *EGFR* mutations were not found in the collective investigated. The plot at the bottom shows the percentage of tumours expressing *EGFR*. Carcinoids present with elevated *EGFR* expression compared to carcinomas.](jcav07p2165g003){#F2}

![The plot at the top is showing the percentage of tumours with inactivating mutations in the *TP53* gene. The plot at the bottom shows the percentage of tumours with high *MDM2* expression. MDM2 overexpression is one possible mechanism to avoid TP53-dependet apoptosis and cell senescence.](jcav07p2165g004){#F3}

###### 

Overview of all genes covered by the NGS cancer hotspot panel. The Panel consists of two-times 221 probes for paired-end sequencing covering 221 mutational hotspots in 48 genes.

  ABL1     AKT1     ALK       APC      ATM      BRAF    CDH1     CDKN2A
  -------- -------- --------- -------- -------- ------- -------- --------
  CSF1R    CTNNB1   EGFR      ERBB2    ERBB4    FBXW7   FGFR1    FGFR2
  FGFR3    FLT3     GNA11     GNAQ     GNAS     HNF1A   HRAS     IDH1
  JAK2     JAK3     KDR       KIT      KRAS     MET     MLH1     MPL
  NOTCH1   NPM1     NRAS      PDGFRA   PIK3CA   PTEN    PTPN11   RB1
  RET      SMAD4    SMARCB1   SMO      SRC      STK11   TP53     VHL

###### 

Results of the gene expression analysis. Minimum, maximum and median for all 13 therapy relevant markers in the overall cohort of pulmonary neuroendocrine tumours is shown. Additionally, the mean value of tumours expressing the mentioned markers as well as the percentage of tumours expressing these markers is shown for each entity. Besides, the number of cases showing an outstanding expression level, including minimum and maximum value, is listed.

![](jcav07p2165g001)

###### 

Overview of results of the biomarker screening. Data for the percentage of tumours expressing each marker as well as the percentage of tumours showing inactivating genetic variants are shown.

  BRAF               0%           0%          11%         6%
  ----------- ------ ----- ------ ----- ----- ----- ----- -----
  **EGFR**    88%    6%    100%   12%   56%   6%    60%   18%
  ERBB2              12%          12%         16%         24%
  **FAS**     63%          23%          31%         20%   
  **FGFR1**   100%   0%    92%    6%    63%   5%    80%   0%
  **FIGF**    38%          0%           31%         7%    
  **FLT4**    69%          38%          13%         20%   
  HRAS               0%           0%          0%          0%
  **IGF1**    88%          38%          56%         53%   
  **IGF2**    88%          85%          56%         87%   
  **KDR**     69%    0%    54%    6%    31%   0%    40%   0%
  KIT                0%           12%         0%          0%
  KRAS               0%           6%          11%         0%
  **MDM2**    81%          77%          50%         93%   
  **MET**     69%    0%    62%    12%   31%   5%    60%   0%
  **MTOR**    81%          100%         44%         80%   
  NOTCH1             0%           0%          0%          0%
  NRAS               0%           0%          0%          6%
  PIK3CA             0%           6%          0%          24%
  RET                6%           6%          5%          18%
  TP53               0%           0%          63%         65%

[^1]: CONFLICT OF INTEREST: All authors disclose any affiliations that are considered to be relevant and important with any organization that to our knowledge has any direct interest in the subject matter discussed.
